CA2490197A1 - Apparatus for polynucleotide detection and quantitation - Google Patents
Apparatus for polynucleotide detection and quantitation Download PDFInfo
- Publication number
- CA2490197A1 CA2490197A1 CA002490197A CA2490197A CA2490197A1 CA 2490197 A1 CA2490197 A1 CA 2490197A1 CA 002490197 A CA002490197 A CA 002490197A CA 2490197 A CA2490197 A CA 2490197A CA 2490197 A1 CA2490197 A1 CA 2490197A1
- Authority
- CA
- Canada
- Prior art keywords
- connecting means
- permits
- polynucleotide
- amplification
- sequence identifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 177
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 177
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 177
- 238000001514 detection method Methods 0.000 title claims description 22
- 230000003321 amplification Effects 0.000 claims abstract description 167
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 167
- 238000004458 analytical method Methods 0.000 claims abstract description 150
- 238000012546 transfer Methods 0.000 claims abstract description 74
- 238000000605 extraction Methods 0.000 claims abstract description 71
- 238000010195 expression analysis Methods 0.000 claims abstract description 34
- 239000012620 biological material Substances 0.000 claims abstract description 11
- 239000011541 reaction mixture Substances 0.000 claims description 52
- 238000005251 capillar electrophoresis Methods 0.000 claims description 49
- 238000006243 chemical reaction Methods 0.000 claims description 43
- 238000003752 polymerase chain reaction Methods 0.000 claims description 38
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 25
- 238000010839 reverse transcription Methods 0.000 claims description 17
- 108020004635 Complementary DNA Proteins 0.000 claims description 10
- 108020004999 messenger RNA Proteins 0.000 claims description 10
- 238000011002 quantification Methods 0.000 claims description 10
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 7
- 239000012530 fluid Substances 0.000 abstract description 26
- 239000000523 sample Substances 0.000 description 115
- 239000000047 product Substances 0.000 description 68
- 238000000034 method Methods 0.000 description 52
- 108020004414 DNA Proteins 0.000 description 35
- 239000013615 primer Substances 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 19
- 239000000463 material Substances 0.000 description 14
- 238000001962 electrophoresis Methods 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000012472 biological sample Substances 0.000 description 11
- 239000000758 substrate Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000004891 communication Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 102100034343 Integrase Human genes 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- -1 i.e. Proteins 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 238000009833 condensation Methods 0.000 description 6
- 230000005494 condensation Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003792 electrolyte Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000001712 DNA sequencing Methods 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 238000005086 pumping Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 241000713838 Avian myeloblastosis virus Species 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000013307 optical fiber Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ZMERMCRYYFRELX-UHFFFAOYSA-N 5-{[2-(iodoacetamido)ethyl]amino}naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1NCCNC(=O)CI ZMERMCRYYFRELX-UHFFFAOYSA-N 0.000 description 2
- OQHKPJAZGYJYTB-UHFFFAOYSA-N 6-(bromomethyl)-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC(CBr)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 OQHKPJAZGYJYTB-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 2
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 2
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 2
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008238 biochemical pathway Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005370 electroosmosis Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000011223 gene expression profiling Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- AHEWZZJEDQVLOP-UHFFFAOYSA-N monobromobimane Chemical compound BrCC1=C(C)C(=O)N2N1C(C)=C(C)C2=O AHEWZZJEDQVLOP-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- ORUDTFXLZCCWNY-UHFFFAOYSA-N pyrene-1,2,3-trisulfonic acid Chemical class C1=CC=C2C=CC3=C(S(O)(=O)=O)C(S(=O)(=O)O)=C(S(O)(=O)=O)C4=CC=C1C2=C43 ORUDTFXLZCCWNY-UHFFFAOYSA-N 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- JBRZTFJDHDCESZ-UHFFFAOYSA-N AsGa Chemical compound [As]#[Ga] JBRZTFJDHDCESZ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 241000243251 Hydra Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 208000037280 Trisomy Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000001818 capillary gel electrophoresis Methods 0.000 description 1
- 238000005515 capillary zone electrophoresis Methods 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 238000012912 drug discovery process Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000001368 germline stem cell Anatomy 0.000 description 1
- 238000000892 gravimetry Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229910021420 polycrystalline silicon Inorganic materials 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920005591 polysilicon Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000012085 transcriptional profiling Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/0099—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor comprising robots or similar manipulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L7/00—Heating or cooling apparatus; Heat insulating devices
- B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Robotics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Clinical Laboratory Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39026902P | 2002-06-20 | 2002-06-20 | |
| US60/390,269 | 2002-06-20 | ||
| PCT/US2003/019518 WO2004001376A2 (en) | 2002-06-20 | 2003-06-19 | Apparatus for polynucleotide detection and quantitation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2490197A1 true CA2490197A1 (en) | 2003-12-31 |
Family
ID=30000534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002490197A Abandoned CA2490197A1 (en) | 2002-06-20 | 2003-06-19 | Apparatus for polynucleotide detection and quantitation |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20040014117A1 (enExample) |
| EP (1) | EP1532273A4 (enExample) |
| JP (2) | JP2005529626A (enExample) |
| KR (1) | KR101086611B1 (enExample) |
| CN (2) | CN100396789C (enExample) |
| AU (2) | AU2003243691A1 (enExample) |
| CA (1) | CA2490197A1 (enExample) |
| WO (1) | WO2004001376A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7846315B2 (en) * | 2002-01-28 | 2010-12-07 | Qiagen Sciences, Llc | Integrated bio-analysis and sample preparation system |
| JP4501430B2 (ja) * | 2004-01-08 | 2010-07-14 | カシオ計算機株式会社 | 検査装置、検査方法及び合成装置 |
| US20070295917A1 (en) * | 2004-01-26 | 2007-12-27 | Applera Corporation | Single excitation wavelength fluorescent detection system |
| TWI391492B (zh) * | 2007-11-20 | 2013-04-01 | Quanta Comp Inc | 自動化遺傳物質處理系統及方法 |
| WO2010141131A1 (en) | 2009-06-04 | 2010-12-09 | Lockheed Martin Corporation | Multiple-sample microfluidic chip for dna analysis |
| CA2814720C (en) | 2010-10-15 | 2016-12-13 | Lockheed Martin Corporation | Micro fluidic optic design |
| JP5722001B2 (ja) * | 2010-11-10 | 2015-05-20 | 株式会社日立ハイテクノロジーズ | 遺伝子検査方法及び検査装置 |
| US9506117B2 (en) | 2012-02-21 | 2016-11-29 | Oslo Universitetssykehus Hf | Methods and biomarkers for detection and prognosis of cervical cancer |
| US9322054B2 (en) | 2012-02-22 | 2016-04-26 | Lockheed Martin Corporation | Microfluidic cartridge |
| CN103352002B (zh) * | 2012-07-05 | 2015-09-02 | 卡尤迪生物科技（北京）有限公司 | 基因扩增及基因检测一体化系统 |
| WO2014039963A1 (en) * | 2012-09-10 | 2014-03-13 | Biofire Diagnostics, Inc. | Multiple amplification cycle detection |
| DE102013200193A1 (de) * | 2013-01-09 | 2014-07-10 | Hamilton Bonaduz Ag | Probenverarbeitungssystem mit Dosiervorrichtung und Thermocycler |
| US10844424B2 (en) | 2013-02-20 | 2020-11-24 | Bionano Genomics, Inc. | Reduction of bias in genomic coverage measurements |
| EP2959015B1 (en) | 2013-02-20 | 2020-11-04 | Bionano Genomics, Inc. | Characterization of molecules in nanofluidics |
| GB201401584D0 (en) * | 2014-01-29 | 2014-03-19 | Bg Res Ltd | Intelligent detection of biological entities |
| CN106164295B (zh) | 2014-02-25 | 2020-08-11 | 生物纳米基因公司 | 减小基因组覆盖测量中的偏差 |
| CN105022900B (zh) * | 2015-08-19 | 2018-02-09 | 电子科技大学 | 基于热固耦合分析的重型数控立车静压转台结构优化方法 |
| CN108359604A (zh) * | 2018-01-25 | 2018-08-03 | 山东百多安医疗器械有限公司 | 一种干细胞种子输送及微环境调节系统 |
| JP2022515782A (ja) | 2018-12-19 | 2022-02-22 | ニュークレイン リミテッド ライアビリティ カンパニー | 分子診断のための装置および方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0311440B1 (en) * | 1987-10-09 | 1992-06-24 | Seiko Instruments Inc. | Apparatus for carrying out a liquid reaction |
| US5169511A (en) * | 1988-11-29 | 1992-12-08 | Isco, Inc. | Capillary electrophoresis technique |
| CA2031912A1 (en) * | 1989-12-22 | 1991-06-23 | Robert Fred Pfost | Heated cover device |
| US5935522A (en) * | 1990-06-04 | 1999-08-10 | University Of Utah Research Foundation | On-line DNA analysis system with rapid thermal cycling |
| JP3011987B2 (ja) * | 1990-10-11 | 2000-02-21 | 旭化成工業株式会社 | 固相化プライマーを用いる逆転写酵素の測定法 |
| KR100236506B1 (ko) * | 1990-11-29 | 2000-01-15 | 퍼킨-엘머시터스인스트루먼츠 | 폴리머라제 연쇄 반응 수행 장치 |
| US6403367B1 (en) * | 1994-07-07 | 2002-06-11 | Nanogen, Inc. | Integrated portable biological detection system |
| US5498545A (en) * | 1994-07-21 | 1996-03-12 | Vestal; Marvin L. | Mass spectrometer system and method for matrix-assisted laser desorption measurements |
| DE69525036T2 (de) * | 1994-11-14 | 2002-08-01 | Trustees Of The University Of Pennsylvania, Philadelphia | Gerät zur amplifikation von polynukleotiden im mesomassstab |
| US5710628A (en) * | 1994-12-12 | 1998-01-20 | Visible Genetics Inc. | Automated electrophoresis and fluorescence detection apparatus and method |
| US6168948B1 (en) * | 1995-06-29 | 2001-01-02 | Affymetrix, Inc. | Miniaturized genetic analysis systems and methods |
| US5856174A (en) * | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
| US5567294A (en) * | 1996-01-30 | 1996-10-22 | Board Of Governors, University Of Alberta | Multiple capillary biochemical analyzer with barrier member |
| EP0909389A2 (en) * | 1996-07-05 | 1999-04-21 | Beckman Coulter, Inc. | Automated sample processing system |
| JP4000605B2 (ja) * | 1996-07-24 | 2007-10-31 | 株式会社日立製作所 | Ｄｎａ試料調整装置及びこれを用いる電気泳動分析装置 |
| US6027627A (en) * | 1997-06-30 | 2000-02-22 | Spectrumedix Corporation | Automated parallel capillary electrophoretic system |
| US6207031B1 (en) * | 1997-09-15 | 2001-03-27 | Whitehead Institute For Biomedical Research | Methods and apparatus for processing a sample of biomolecular analyte using a microfabricated device |
| US6126804A (en) * | 1997-09-23 | 2000-10-03 | The Regents Of The University Of California | Integrated polymerase chain reaction/electrophoresis instrument |
| US6979424B2 (en) * | 1998-03-17 | 2005-12-27 | Cepheid | Integrated sample analysis device |
| JP3713970B2 (ja) * | 1998-09-09 | 2005-11-09 | 株式会社日立製作所 | 特異的遺伝子断片の分離採取装置 |
| US6372484B1 (en) * | 1999-01-25 | 2002-04-16 | E.I. Dupont De Nemours And Company | Apparatus for integrated polymerase chain reaction and capillary electrophoresis |
| JP2000346828A (ja) * | 1999-06-02 | 2000-12-15 | Hitachi Ltd | 電気泳動装置 |
| JP4071907B2 (ja) * | 1999-11-29 | 2008-04-02 | オリンパス株式会社 | 自動核酸検査装置 |
| EP1276900A2 (en) * | 2000-01-11 | 2003-01-22 | Maxygen, Inc. | Integrated systems and methods for diversity generation and screening |
| JP4103302B2 (ja) * | 2000-05-15 | 2008-06-18 | 株式会社日立製作所 | キャピラリアレイを用いた電気泳動装置及びそれに用いられるサンプルプレートアセンブリ |
| US6783649B2 (en) * | 2000-12-01 | 2004-08-31 | Cetek Corporation | High throughput capillary electrophoresis system |
| DE60220497T2 (de) * | 2001-01-26 | 2008-01-31 | Biocal Technology, Inc., Irvine | Optische detektion in einem mehrkanaligen bioseparationssystem |
| JP2004532384A (ja) * | 2001-01-26 | 2004-10-21 | バイオカル テクノロジー，インコーポレイティド | マルチチャネル生物分離カートリッジ |
| US20040266021A9 (en) * | 2001-01-26 | 2004-12-30 | Andras Guttman | Multicapillary fraction collection system and method |
| US7250099B2 (en) * | 2002-12-13 | 2007-07-31 | Biocal Technology, Inc. | Optical detection alignment coupling apparatus |
| US7846315B2 (en) * | 2002-01-28 | 2010-12-07 | Qiagen Sciences, Llc | Integrated bio-analysis and sample preparation system |
| US7445893B2 (en) * | 2002-04-12 | 2008-11-04 | Primera Biosystems, Inc. | Sampling method for amplification reaction analysis |
-
2003
- 2003-06-19 US US10/464,941 patent/US20040014117A1/en not_active Abandoned
- 2003-06-19 KR KR1020047020741A patent/KR101086611B1/ko not_active Expired - Fee Related
- 2003-06-19 CN CNB038172453A patent/CN100396789C/zh not_active Expired - Fee Related
- 2003-06-19 AU AU2003243691A patent/AU2003243691A1/en not_active Abandoned
- 2003-06-19 JP JP2004516034A patent/JP2005529626A/ja active Pending
- 2003-06-19 EP EP03761193A patent/EP1532273A4/en not_active Ceased
- 2003-06-19 CA CA002490197A patent/CA2490197A1/en not_active Abandoned
- 2003-06-19 CN CN2008100947129A patent/CN101348763B/zh not_active Expired - Fee Related
- 2003-06-19 WO PCT/US2003/019518 patent/WO2004001376A2/en not_active Ceased
-
2009
- 2009-04-20 AU AU2009201529A patent/AU2009201529B2/en not_active Ceased
-
2010
- 2010-04-30 JP JP2010104811A patent/JP5258835B2/ja not_active Expired - Fee Related
-
2011
- 2011-12-06 US US13/312,584 patent/US20120100600A1/en not_active Abandoned
-
2012
- 2012-12-17 US US13/716,615 patent/US20130189768A1/en not_active Abandoned
-
2014
- 2014-01-13 US US14/153,600 patent/US20140256029A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004001376A2 (en) | 2003-12-31 |
| US20040014117A1 (en) | 2004-01-22 |
| CN101348763B (zh) | 2012-07-18 |
| WO2004001376A3 (en) | 2004-02-26 |
| CN100396789C (zh) | 2008-06-25 |
| KR20050021997A (ko) | 2005-03-07 |
| EP1532273A4 (en) | 2009-11-18 |
| AU2003243691A1 (en) | 2004-01-06 |
| EP1532273A2 (en) | 2005-05-25 |
| CN1668766A (zh) | 2005-09-14 |
| AU2009201529A1 (en) | 2009-05-21 |
| CN101348763A (zh) | 2009-01-21 |
| AU2009201529B2 (en) | 2011-07-28 |
| JP2010207237A (ja) | 2010-09-24 |
| US20120100600A1 (en) | 2012-04-26 |
| US20130189768A1 (en) | 2013-07-25 |
| JP2005529626A (ja) | 2005-10-06 |
| JP5258835B2 (ja) | 2013-08-07 |
| US20140256029A1 (en) | 2014-09-11 |
| KR101086611B1 (ko) | 2011-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009201529B2 (en) | Apparatus For Polynucleotide Detection and Quantitation | |
| US10252261B2 (en) | Handling liquid samples | |
| US5716825A (en) | Integrated nucleic acid analysis system for MALDI-TOF MS | |
| US6977163B1 (en) | Methods and systems for performing multiple reactions by interfacial mixing | |
| JP2011062119A (ja) | 生体試料定量用チップ | |
| JP6665090B2 (ja) | マイクロ流体装置並びにかかる装置に試薬及び生体試料を供給するための配置 | |
| JP2018520706A (ja) | 試料採取からｎｇｓライブラリ調製までの自動化 | |
| US20240123447A1 (en) | Methods and related aspects for multiplexed analyte detection using sequential magnetic particle elution | |
| JP2005538734A (ja) | 自動液体処理中のｒｎａ及び逆転写酵素の保存 | |
| EP1718411B1 (en) | A device for analysing an interaction between target and probe molecules | |
| KR20050075436A (ko) | 증폭 반응 분석을 위한 샘플링 방법과 장치 | |
| JP5505646B2 (ja) | 生体試料定量方法 | |
| US20050227261A1 (en) | Method for sequencing-by-synthesis | |
| US20050089875A1 (en) | Quantitative analysis of expression profiling information produced at various stages of an amplification process | |
| Blakey et al. | General Approach to Molecular Pathology | |
| HK1127066B (en) | Droplet-based biochemistry | |
| HK1200498B (zh) | 生化分析的系统、设备和方法 | |
| HK1127066A1 (en) | Droplet-based biochemistry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20150122 |